Safety and effectiveness of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the SPUM-ACS study
Main finding · MACEResult — go to the resultHazard ratio 0.70 95% CI 0.49–0.99Authors' conclusion
In patients with ACS undergoing percutaneous coronary intervention and receiving potent P2Y12 inhibitors, we observed a reduced risk of MACE and an increased risk of major bleedings at 1 year in patients treated with GPI.
Study context
- Population
- Contemporary acute coronary syndrome (ACS) patients (SPUM-ACS, 2009–2017)Propensity score-matched (PSM) population 1992
- Participants
- 4,395 patients
- Exposure
- GPI vs no GPI
- Outcome
- Major adverse cardiovascular events (MACE):
- All-cause death
- Non-fatal MI
- Non-fatal stroke
- Follow-up
- 1 year
Methodological detailsmulticentre, propensity-score matched
- Multicentre
- Propensity-score matched
Main finding
MACE
Hazard ratio
0.70
95% CI 0.49–0.99
GPIvs No GPI
HR 0.70 (95% CI 0.49–0.99)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| NACEPSM adjusted | 0.87 (0.65–1.17) | |
| 0.512Hazard ratio (log scale) |
Total coronary occlusion and thrombus at angiography
- Total coronary occlusion, GPI vs no GPI
- 56% vs. 35%, P < 0.001
- Thrombus, GPI vs no GPI
- 60% vs. 35%, P < 0.001
Subgroups
- Results consistent across all subgroups
Safety
| Outcome | HR (95% CI) | |
|---|---|---|
| Any bleedingPSM adjusted | 1.46 (1.06–1.99) | |
| Major bleedingPSM adjusted | 1.73 (1.09–2.76) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Safety and effectiveness of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the SPUM-ACS study. Eur Heart J Cardiovasc Pharmacother. Published 11 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →